Long term survival of HER2-positive early breast cancer treated withtrastuzumab-based adjuvant regimen: A large cohort study fromclinical practice

Martina Bonifazi, Matteo Franchi, Marta Rossi, Alberto Zambelli, Lorenzo Moja, Antonella Zambon, Giovanni Corrao, Carlo La Vecchia, Carlo Zocchetti, Eva Negri

Research output: Contribution to journalArticlepeer-review

Abstract

Trastuzumab-based regimens for the adjuvant treatment of HER2-positive early breast cancer significantly prolonged overall survival (OS) and disease free survival (DFS) in large randomized trials, with sustained benefits at four-year follow-up. We assessed long-term survival estimates and predictors in a large cohort of Italian women with early breast cancer treated with trastuzumab in clinical practice. Through a record linkage between five regional healthcare databases, we identified women treated with trastuzumab for early breast cancer in Lombardy (2006-2009). DFS and OS were estimated using the Kaplan-Meier method, and independent predictors were assessed using proportional hazard models. 2046 women received trastuzumab in early breast cancer adjuvant setting. Overall, the proportion of patients surviving free of disease was 93.9% at one year, 85.8% at 2 years, 79.4% at 3 years, and 75.0% at 4 years. OS estimates were 98.7%, 95.4%, 91.5% and 89.4% at 1, 2, 3 and 4 years, respectively. Significant independent predictors of worse survival outcomes were age

Original languageEnglish
Pages (from-to)573-578
Number of pages6
JournalBreast
Volume23
Issue number5
DOIs
Publication statusPublished - Oct 1 2014

Keywords

  • Adjuvant therapy
  • Disease-free survival
  • Early breast cancer
  • Predictors
  • Survival
  • Trastuzumab

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Fingerprint Dive into the research topics of 'Long term survival of HER2-positive early breast cancer treated withtrastuzumab-based adjuvant regimen: A large cohort study fromclinical practice'. Together they form a unique fingerprint.

Cite this